GlassScriptPhysician profile
William Rushing
NPI 1790891679
$2,897.58
in general payments reported to CMS, 2019-2025
26 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $529 · 2021: $676 · 2022: $358 · 2023: $351 · 2024: $322 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.70 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.53 | 2019-2023 | Liletta |
| Amgen INC. | $486.89 | 2019-2025 | Evenity, Prolia |
| Shield Therapeutics INC | $198.17 | 2022-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $188.67 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $147.93 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $147.28 | 2019-2023 | |
| Allergan, INC. | $127.18 | 2020 | |
| Astellas Pharma US INC | $118.56 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $108.98 | 2023-2025 | |
| Organon LLC | $83.24 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $69.75 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $63.10 | 2021-2025 | Novasure, Myosure Tissue Removal Device |
| Daiichi Sankyo INC. | $46.71 | 2021 | |
| Radius Health, INC. | $45.13 | 2020-2023 | Tymlos |
| Medtronic, INC. | $41.71 | 2023 | Sonicision |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.01 | 2019-2021 | |
| Sage Therapeutics, LLC | $37.36 | 2025 | |
| Roche Diagnostics Corporation | $29.29 | 2019 | |
| Minerva Surgical, INC | $26.19 | 2019-2021 | |
| Coopersurgical, INC. | $20.28 | 2019 | |
| Kci USA, INC. | $16.05 | 2023 | Prevena |
| Applied Medical Resources Corporation | $15.39 | 2019 | |
| Therapeuticsmd, INC. | $15.37 | 2020 | |
| Myovant Sciences INC. | $12.63 | 2022 | |
| Avion Pharmaceuticals | $12.07 | 2021 | |
| Evofem Biosciences, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.